[go: up one dir, main page]

MX367519B - Compuestos triazolicos como bloqueadores de canales de calcio tipo t. - Google Patents

Compuestos triazolicos como bloqueadores de canales de calcio tipo t.

Info

Publication number
MX367519B
MX367519B MX2017003362A MX2017003362A MX367519B MX 367519 B MX367519 B MX 367519B MX 2017003362 A MX2017003362 A MX 2017003362A MX 2017003362 A MX2017003362 A MX 2017003362A MX 367519 B MX367519 B MX 367519B
Authority
MX
Mexico
Prior art keywords
channel blockers
calcium channel
type calcium
triazole compounds
compounds
Prior art date
Application number
MX2017003362A
Other languages
English (en)
Other versions
MX2017003362A (es
Inventor
Siegrist Romain
Stamm Simon
Heidmann Bibia
Bezencon Olivier
Gatfield John
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MX2017003362A publication Critical patent/MX2017003362A/es
Publication of MX367519B publication Critical patent/MX367519B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a compuestos de la fórmula (I) donde X, Y, R1, R2, (R4)n y (R5)m son como se definió en la descripción y a sales farmacéuticamente aceptables de dichos compuestos. Estos compuestos son útiles como bloqueadores de los canales de calcio tipo T.
MX2017003362A 2014-09-15 2015-09-14 Compuestos triazolicos como bloqueadores de canales de calcio tipo t. MX367519B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2014069592 2014-09-15
PCT/EP2015/070934 WO2016041892A1 (en) 2014-09-15 2015-09-14 Triazole compounds as t-type calcium channel blockers

Publications (2)

Publication Number Publication Date
MX2017003362A MX2017003362A (es) 2017-06-28
MX367519B true MX367519B (es) 2019-08-26

Family

ID=54106361

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003362A MX367519B (es) 2014-09-15 2015-09-14 Compuestos triazolicos como bloqueadores de canales de calcio tipo t.

Country Status (16)

Country Link
US (1) US10246426B2 (es)
EP (1) EP3194374B1 (es)
JP (1) JP6500092B2 (es)
KR (1) KR102424750B1 (es)
CN (1) CN107074822B (es)
AU (1) AU2015317022B2 (es)
CA (1) CA2956816C (es)
CL (1) CL2017000616A1 (es)
EA (1) EA032873B1 (es)
ES (1) ES2693052T3 (es)
IL (1) IL251042A0 (es)
MX (1) MX367519B (es)
PH (1) PH12017500447A1 (es)
PL (1) PL3194374T3 (es)
SG (1) SG11201701998XA (es)
WO (1) WO2016041892A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR100712A1 (es) 2014-06-03 2016-10-26 Actelion Pharmaceuticals Ltd Compuestos de pirazol como bloqueadores de los canales de calcio tipo t
HUE058360T2 (hu) 2016-12-16 2022-07-28 Idorsia Pharmaceuticals Ltd T-típusú kalcium-csatorna blokkolót tartalmazó gyógyszerészeti kombináció
US10899695B2 (en) 2017-02-06 2021-01-26 Idorsia Pharmaceuticals Ltd Process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
WO2019008034A1 (en) 2017-07-05 2019-01-10 Idorsia Pharmaceuticals Ltd CRYSTALLINE FORM OF N- [1- (5-CYANO-PYRIDIN-2-YLMETHYL) -1H-PYRAZOL-3-YL] -2- [4- (1-TRIFLUOROMETHYL-CYCLOPROPYL) -PHENYL] -ACETAMIDE
CN114340670A (zh) 2019-07-11 2022-04-12 普拉克西斯精密药物股份有限公司 T-型钙通道调节剂的制剂及其使用方法
WO2023240205A1 (en) 2022-06-10 2023-12-14 Neurocrine Biosciences, Inc. Deuterated compounds

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE217865T1 (de) 1994-06-24 2002-06-15 Euro Celtique Sa Verbindungen zur hemmung von phosphodiesrerase iv
AU730224B2 (en) 1996-12-23 2001-03-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
WO2002053160A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating glaucoma ivb
WO2002053101A2 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
ATE455104T1 (de) 2001-11-01 2010-01-15 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
ES2292854T3 (es) 2001-12-18 2008-03-16 MERCK & CO., INC. Moduladores triazol sustituidos con heteroarilo del receptor-5 metabotropico de glumatamato.
AU2002359714B2 (en) 2001-12-18 2006-12-21 Merck Sharp & Dohme Corp. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
SE0201658D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
CA2520870A1 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
EP1613617A4 (en) 2003-04-04 2009-02-18 Merck & Co Inc METABOTROPIC GLUTAMATE RECEPTOR-5 DIARYLSUBSTITUTED TRIAZOLE MODULATORS
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
GB0328796D0 (en) 2003-12-12 2004-01-14 Biofocus Plc Compounds which interact with the G-protein coupled receptor family
GB0508472D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
GB0508463D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
WO2007073497A2 (en) 2005-12-22 2007-06-28 Icagen, Inc. Calcium channel antagonists
DK2010493T3 (en) 2006-04-12 2016-05-02 Merck Sharp & Dohme PYRIDYLAMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS
AU2007278261A1 (en) 2006-07-24 2008-01-31 F. Hoffmann-La Roche Ag Pyrazoles as glucokinase activators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
WO2008085888A1 (en) 2007-01-05 2008-07-17 Arena Pharmaceuticals, Inc. G protein-coupled receptor and modulators thereof for the treatment of gaba-related neurological disorders including sleep-related disorders
AU2008266883B2 (en) 2007-06-20 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
DE102007047738A1 (de) * 2007-10-05 2009-04-09 Merck Patent Gmbh Imidazolderivate
ES2446932T3 (es) 2007-10-08 2014-03-10 Advinus Therapeutics Private Limited Derivados de acetamida como activadores de glucoquinasa, su procedimiento y aplicaciones en medicina
CA2703471A1 (en) 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Pyrazinyl amide t-type calcium channel antagonists
AU2008317353B2 (en) 2007-10-24 2014-08-07 Merck Sharp & Dohme Llc Heterocycle phenyl amide T-type calcium channel antagonists
JP2011500808A (ja) 2007-10-24 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 複素環アミドｔ型カルシウムチャネルアンタゴニスト
CA2685716A1 (en) 2008-04-04 2009-10-08 Summit Corporation Plc Compounds for treating muscular dystrophy
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
JP2012513409A (ja) 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
JP2012524754A (ja) * 2009-04-24 2012-10-18 グラクソ グループ リミテッド Ｃｒａｃチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド
MX2011012712A (es) * 2009-05-29 2012-01-30 Raqualia Pharma Inc Derivados de carboxamida sustituidos con arilo como bloqueadores del canal de calcio o sodio.
WO2011022315A1 (en) 2009-08-19 2011-02-24 Merck Sharp & Dohme Corp. Pyrazinyl phenyl amide t-type calcium channel antagonists
US8987310B2 (en) 2009-10-30 2015-03-24 Merck Sharp & Dohme Corp. Heterocycle amide T-type calcium channel antagonists
CA2782885A1 (en) 2009-12-21 2011-07-14 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
EP2530078A1 (en) 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
EP2402327B1 (en) 2010-06-29 2018-03-07 Impetis Biosciences Ltd. Acetamide compounds as glucokinase activators, their process and medicinal applications
KR20120063283A (ko) 2010-12-07 2012-06-15 제일약품주식회사 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
AR096393A1 (es) 2013-05-23 2015-12-30 Bayer Cropscience Ag Compuestos heterocíclicos pesticidas
KR101685993B1 (ko) 2014-05-15 2016-12-13 한국과학기술연구원 전압개폐 칼슘이온채널 억제 활성화능을 갖는 ｎ-(피라졸릴메틸)아릴설폰아마이드 화합물 및 이를 포함하는 약학적 조성물
AR100712A1 (es) * 2014-06-03 2016-10-26 Actelion Pharmaceuticals Ltd Compuestos de pirazol como bloqueadores de los canales de calcio tipo t
HUE058156T2 (hu) 2015-01-30 2022-07-28 Neurocrine Biosciences Inc Helyettesített triazolok és ezekkel kapcsolatos eljárások

Also Published As

Publication number Publication date
MX2017003362A (es) 2017-06-28
WO2016041892A1 (en) 2016-03-24
US20180230109A1 (en) 2018-08-16
CN107074822B (zh) 2020-01-03
CL2017000616A1 (es) 2017-11-24
PH12017500447A1 (en) 2017-07-31
KR20170052686A (ko) 2017-05-12
BR112017005179A2 (pt) 2017-12-05
EA201790613A1 (ru) 2017-12-29
CA2956816A1 (en) 2016-03-24
IL251042A0 (en) 2017-04-30
BR112017005179A8 (pt) 2017-12-26
AU2015317022B2 (en) 2020-01-16
AU2015317022A1 (en) 2017-04-27
CN107074822A (zh) 2017-08-18
ES2693052T3 (es) 2018-12-07
EA201790613A8 (ru) 2018-10-31
SG11201701998XA (en) 2017-04-27
CA2956816C (en) 2023-02-14
EP3194374B1 (en) 2018-08-01
KR102424750B1 (ko) 2022-07-22
PL3194374T3 (pl) 2019-01-31
JP2017532309A (ja) 2017-11-02
US10246426B2 (en) 2019-04-02
EA032873B1 (ru) 2019-07-31
JP6500092B2 (ja) 2019-04-10
EP3194374A1 (en) 2017-07-26

Similar Documents

Publication Publication Date Title
PH12016502230B1 (en) Pyrazole compounds and their use as t-type calcium channel blockers
MX2018006148A (es) Inhibidores de cxcr2.
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2020004504A (es) Derivados de fenoximetilo.
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
MX2018001430A (es) Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MX2020001278A (es) Sintesis de compuestos de carbamoilpiridona policiclica.
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
PH12017500447A1 (en) Triazole compounds as t-type calcium channel blockers
AU2014375265A1 (en) Novel pyrazolyl-heteroarylamides as pesticides
IN2015DN00960A (es)
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
PH12016501997B1 (en) Cycloalkyl-linked diheterocycle derivatives
IN2014CH00151A (es)
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
PH12018500406A1 (en) Bicyclic compounds as atx inhibitors
PH12018500407A1 (en) New bicyclic compounds as dual atx/ca inhibitors
ZA201702615B (en) Triazole compounds as t-type calcium channel blockers
MX2018011117A (es) Forma cristalina.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: IDORSIA PHARMACEUTICALS LTD

FG Grant or registration